1. Bangladesh Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Asiatic Laboratories Ltd

Asiatic Laboratories Ltd

DDSE:ASIATICLAB
110.20
BDT
+4.50
(+4.26%)
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

Company Profile APIChatGPT
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Dhaka Bangladesh
IPO Date
Mar 6, 2024
Website
asiaticlaboratories.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Asiatic Laboratories Limited is a Bangladesh-based pharmaceutical company that manufactures, markets, and distributes a diversified portfolio of biological and non-biological pharmaceutical formulations. Founded in 1970 and headquartered in Dhaka, Bangladesh, the company operates its primary manufacturing complex in the Tongi Industrial Area of Gazipur, producing generic medicines in compliance with World Health Organization Current Good Manufacturing Practice (WHO-cGMP) standards. The company's product portfolio spans more than 260 commercial formulations across extensive therapeutic categories; antibacterial and broad-spectrum antibiotic medications, including Cefixime (Afixime), Ciprofloxacin (Cip), Cefuroxime Axetil (Ceroxime), Azithromycin (Asizith), Cefpodoxime (Cefipod), and Levofloxacin (Asilee); non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics, including Aceclofenac (Ena), Naproxen (Pairox), Diclofenac Sodium (Locopain), Paracetamol formulations (Tempol Plus), and Ketorolac Tromethamine (Surpim); gastrointestinal agents, antiulcerants, and antiemetics, including Ondansetron (Onlit), gastroprokinetics, and laxatives; central nervous system (CNS) and antipsychotic therapies; respiratory agents, bronchodilators, and antihistamines; vitamins, minerals, and dietary supplements; dermatological creams, gels, and ointments; and sterile ophthalmic preparations. The company manufactures these pharmaceuticals in multiple dosage forms, including solid oral dosage units such as film-coated and enteric-coated tablets and hard gelatin capsules; oral liquid preparations and syrups; topical semisolids; sterile eye drops; and injectable solutions. Asiatic Laboratories supplies its pharmaceutical products to retail pharmacies, government and private hospitals, healthcare clinics, and wholesale pharmaceutical distributors throughout Bangladesh. In recent major developments, Asiatic Laboratories completed its initial public offering (IPO) under the book-building method, raising approximately BDT 950 million and listing its equity shares on the Dhaka Stock Exchange and Chittagong Stock Exchange in March 2024 under the ticker ASIATICLAB. The company has deployed the majority of its IPO capital toward constructing and commissioning a dedicated manufacturing facility for anticancer and oncology therapeutics, procuring specialized high-capacity production machinery, modernizing sterile injectable lines, and repaying existing debt to support long-term capacity expansion and entry into high-barrier therapeutic sectors.